Literature DB >> 4044465

Double beta-lactam therapy in the immunocompromised host.

L S Young.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4044465     DOI： 10.1093/jac/16.1.4

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

1.  Do double-beta-lactam combinations prolong neutropenia in patients undergoing chemotherapy or bone marrow transplantation for hematological disease?

Authors:  C C Kibbler; H G Prentice; R J Sage; A V Hoffbrand; M K Brenner; P Noone
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients.

Authors:  C S Verhagen; B de Pauw; T de Witte; J Janssen; K Williams; P de Mulder; T Bothof
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  Beta-lactamase alteration of beta-lactam inhibitory zones.

Authors:  F Tausk; C W Stratton
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

Review 4.  Neutropenia: antibiotic combinations for empiric therapy.

Authors:  L S Young
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.